Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
EVO · Nasdaq · United States · Pharmaceutical Preparations
In shortEvotec SE is loss-making, burns cash and holds more cash than debt, with revenue stable (+2.0% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -17.9% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -24.6% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -18.9% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -8.9% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.98× | 98/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.33× | 93/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 0.55 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -12.5% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 2 of 5 | 25/100 |
Weight in the score: 20%
| Profitable years (last 5) | 2 of 5 | 40/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 5 | 100/100 |
| Revenue growth volatility | 9.8% | 75/100 |
| Operating margin volatility | 11.2% | 8/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 8.8% | 66/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2024 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
1 older year available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
EUR millions; negative values in parentheses.
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 |
|---|---|---|---|---|---|
| Revenue | 501 | 618 | 751 | 781 | 797 |
| Cost of revenue | 375 | 466 | 577 | 606 | 682 |
| Gross profit | 126 | 152 | 174 | 175 | 115 |
| Research & development | 64 | 72 | 77 | 69 | 51 |
| Selling, general & admin | 77 | 105 | 156 | 170 | 188 |
| Operating income | 49 | 41 | 21 | (48) | (143) |
| Interest expense | 8.5 | 9.3 | 13 | – | – |
| Pre-tax income | 26 | 237 | (154) | (81) | (194) |
| Income tax | 20 | 21 | 22 | 3.3 | 2.1 |
| Net income | 6.3 | 216 | (176) | (84) | (196) |
| Diluted EPS | €0.04 | €1.30 | −€0.99 | −€0.47 | −€1.11 |
| Diluted shares (millions) | 154 | 166 | 177 | 177 | 177 |
1 older year available with the 10-year history. Essential plan, from €8.25/month →
0.55 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
6/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2025 · Data updated Apr 17, 2025